BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zhang Y, Wu W, Sun Q, Ye L, Zhou D, Wang W. linc‑ROR facilitates hepatocellular carcinoma resistance to doxorubicin by regulating TWIST1‑mediated epithelial‑mesenchymal transition. Mol Med Rep 2021;23:340. [PMID: 33760121 DOI: 10.3892/mmr.2021.11979] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Eptaminitaki GC, Stellas D, Bonavida B, Baritaki S. Long non-coding RNAs (lncRNAs) signaling in cancer chemoresistance: From prediction to druggability. Drug Resistance Updates 2022;65:100866. [DOI: 10.1016/j.drup.2022.100866] [Reference Citation Analysis]
2 He Q, Guo P, Bo Z, Yu H, Yang J, Wang Y, Chen G. Noncoding RNA-mediated molecular bases of chemotherapy resistance in hepatocellular carcinoma. Cancer Cell Int 2022;22:249. [PMID: 35945536 DOI: 10.1186/s12935-022-02643-6] [Reference Citation Analysis]
3 Huang S, Li D, Zhuang L, Zhang J, Wu J. Identification of an Epithelial-Mesenchymal Transition-Related Long Non-coding RNA Prognostic Signature to Determine the Prognosis and Drug Treatment of Hepatocellular Carcinoma Patients. Front Med 2022;9:850343. [DOI: 10.3389/fmed.2022.850343] [Reference Citation Analysis]
4 Zhang Z, Gu M, Gu Z, Lou YR. Role of Long Non-Coding RNA Polymorphisms in Cancer Chemotherapeutic Response. J Pers Med 2021;11:513. [PMID: 34199840 DOI: 10.3390/jpm11060513] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]